October 2007 Fingertip Formulary Insights™
Key Findings
- Inconsistency for step therapy: There was no consistent trend across drug classes for step therapy in terms of differences between commercial and Medicare plans.
- Where were the differences? The ARBs demonstrated significantly higher rates of step therapy, with over 35% of Medicare lives having a step therapy in place, as compared to only 15% for commercial lives. In contrast, for Statins, step therapy was much more prevalent for commercial plans (20% of lives) as compared to Medicare (only 5% of lives).
- No differences: For the PPI and Osteoporosis drug classes, there were no meaningful differences in the rates of step therapy between commercial and Medicare plans.
Printable version (PDF 163KB)
Archives
December 2007: Lack of Impact from Two Key Generics in the Anti-depressant Formulary Market
October 2007: Formulary Position Differences between Commercial and Medicare Plans
September 2007: Impact of Patent Loss for Zocor on the Statin Marketplace
- Intro
- Formulary Access
- Trend Analysis
- Prior Authorization
- Quantity Limits
- Step Therapy
- Strategic Implications
Step Therapy
